Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Metformin
62%
Insulin
41%
Diabetes
33%
Insulin Resistance
26%
Glycemic Control
25%
Glucagon-like
24%
Type 2 Diabetic Patients
23%
Glucose-lowering Drugs
21%
Obesity
20%
Insulin Release
19%
Hyperglycemia
18%
Dapagliflozin
17%
Diabetic
16%
Antihyperglycemic
16%
Glucose-dependent Insulinotropic Polypeptide
15%
Insulin Secretion
15%
Thiazolidinediones
13%
Palmitate
11%
Hemoglobin A1c (HbA1c)
11%
Dipeptidyl peptidase-IV (DPP-IV)
11%
Type 2 Diabetes Prevention
11%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
10%
Dipeptidyl peptidase-4 (DPP-4)
10%
Diabetes Management
10%
Hypoglycemia
9%
Weight Loss
9%
A1 Receptor
9%
Antidiabetic Drugs
9%
Clinical Trials
9%
Peroxisome Proliferator-activated Receptor
8%
Diabetic Mice
8%
Glucagon
8%
Placebo
8%
Receptor Agonist
8%
Fatty Acids
8%
Glucose Uptake
8%
Monotherapy
8%
Type 1 Diabetes Mellitus (T1DM)
8%
Rosiglitazone
8%
Amides
8%
Insulin Action
7%
Islet
7%
Plasma Glucose
7%
Cardiovascular Risk
7%
Monocytes
6%
Insulin Sensitivity
6%
Skeletal muscle
6%
Blood Glucose
6%
B Cells
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
93%
Metformin
46%
Antidiabetic Agent
23%
Gastric Inhibitory Polypeptide
20%
Insulin Resistance
19%
Hyperglycemia
18%
Dapagliflozin
17%
Glucagon-Like Peptide-1
15%
Diabetes Mellitus
15%
Ob/Ob Mouse
14%
Hemoglobin A1c
12%
Placebo
11%
Hypoglycemia
10%
Clinical Trial
10%
Monotherapy
10%
Thiazolidinedione
10%
Dipeptidyl Peptidase IV Inhibitor
9%
Incretin
9%
Receptor
9%
Dipeptidyl Peptidase IV
8%
Palmitic Acid
8%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Diabetic Obesity
7%
Fatty Acid
7%
Sulfonylurea
7%
Tablet
7%
Pharmacotherapy
6%
Glucagon Like Peptide 1 [7-36] Amide
6%
Peroxisome Proliferator Activated Receptor
6%
Cardiovascular Risk
5%
Disease
5%
Sibutramine
5%
Glucagon
5%
Rosiglitazone
5%
Pioglitazone
5%
Streptozotocin
5%
Cardiovascular Disease
5%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
67%
Glycon
40%
Diabetes
40%
Glycemic Control
18%
Hyperglycemia
15%
Insulin Release
14%
Antidiabetic Agent
13%
Insulin Resistance
13%
Drug Therapy
13%
Diabetes Mellitus
11%
Hypoglycemia
10%
Patient with Type 2 Diabetes
9%
Blood Glucose
9%
Glucose Uptake
9%
Dapagliflozin
7%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Glucagon
6%
Glucagon Like Peptide 1
6%
Gastric Inhibitory Polypeptide
6%
In Vitro
6%
Dipeptidyl Peptidase-4 Inhibitor
6%
Leptin
6%
Epithelial Cell
6%
Ob/Ob Mouse
6%
Glycemic
6%
Cardiovascular System
5%
Receptor
5%
Oral Antidiabetic Agent
5%
Incretin
5%
Glucagon-Like Peptide-1 Agonist
5%
Cardiovascular Risk
5%
Skeletal Muscle
5%